Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Iron Overload

Interventions

DRUG

Deferasirox

Trial Locations (1)

Novartis Investigative Site, Leipzig